Palisade Bio

Palisade Bio is advancing a novel prodrug platform to create safer, more effective oral therapies for chronic inflammatory and fibrotic diseases, with an initial focus on inflammatory bowel disease (IBD). The company's lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug engineered for selective bioactivation in the ileum and colon, aiming to maximize local efficacy and minimize systemic adverse events. Palisade is preparing to initiate a Phase 2 study in ulcerative colitis, marking a critical inflection point for validating its targeted delivery approach. The strategy leverages proven PDE4 biology to address significant unmet needs in large, chronic disease markets.

A proprietary prodrug platform designed for localized bioactivation, engineering orally administered inactive precursors that are selectively converted to active PDE4 inhibitors at specific disease sites, primarily the gastrointestinal tract.